Monitor final pricing and size of the offering upon effectiveness; the stock will likely face downward pressure from dilution. Watch for execution of the stock repurchase, which could partially offset dilution but is contingent on offering proceeds exceeding $200M. The CEO transition adds management uncertainty, though the CoMpass trial update is neutral to slightly positive for the pipeline timeline.
Price Chart
Executive Summary
Aura Biosciences filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre-funded warrants. The offering size is unspecified but will cause immediate and substantial dilution; proceeds will fund clinical programs and potentially repurchase up to 6,922,870 shares from Matrix Capital if net proceeds exceed $200M. The filing also discloses a CEO transition and that the Phase 3 CoMpass trial is nearing enrollment completion (86 patients as of May 4, 2026).
Key Facts
- Offering of common stock and pre-funded warrants; all terms (size, price) are placeholders pending final pricing.
- Last reported sale price on May 1, 2026 was $7.01 per share; market cap ~$450M.
- Historical net tangible book value of $121.1M ($1.90/share) as of Dec 31, 2025; offering will cause immediate dilution.
- Preliminary cash, cash equivalents, and marketable securities of ~$114.7M as of March 31, 2026.
- Planned stock repurchase of up to 6,922,870 shares (10.8% of outstanding) from Matrix Capital, contingent on net proceeds exceeding $200M.
- CEO transition: Natalie Holles appointed effective April 30, 2026, succeeding founder Elisabet de los Pinos.
- Phase 3 CoMpass trial for bel-sar (early choroidal melanoma) nearing enrollment completion; topline data expected H2 2027.
Financial Impact
Significant dilution from offering; potential repurchase of ~10.8% of outstanding shares if net proceeds >$200M; no revenue or earnings disclosed.
Risk Factors
- Immediate and substantial dilution to existing shareholders.
- Stock repurchase may not occur if net proceeds are ≤$200M, leading to higher share count.
- Clinical-stage biotech with no approved products; reliance on bel-sar Phase 3 data.
- CEO transition introduces execution risk.
- No established public market for pre-funded warrants.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-202458 |
| Document: 0001193125-26-202458-index-headers.html | 0001193125-26-202458 |
| Document: 0001193125-26-202458-index.html | 0001193125-26-202458 |
| Document: 0001193125-26-202458.txt | 0001193125-26-202458 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $6.45 $6.56 | ▲ +1.71% | ▲ +2.27% | $6.26 (−2.95%) |
Aug 21, 2026 9w ago | EFFECT | $7.80 $6.36 | ▲ +18.46% | ▲ +17.94% | $6.26 (+19.74%) |
Aug 11, 2026 11w ago | 8-K | $8.04 $7.20 | ▲ +10.45% | ▲ +9.39% | $6.26 (+22.14%) |
Aug 11, 2026 11w ago | Press Release | $8.04 $7.20 | ▲ +10.45% | ▲ +9.39% | $6.26 (+22.14%) |
Jul 8, 2026 15w ago | 8-K | $7.25 $7.18 | ▼ −0.97% | ▼ −4.24% | $6.26 (−13.66%) |
May 19, 2026 22w ago | Press Release | $7.47 $6.34 | ▼ −15.13% | ▼ −15.87% | $6.26 (−16.20%) |
May 5, 2026 24w ago | 8-K | $8.29 $6.88 | ▲ +17.01% | ▲ +19.79% | $6.26 (+24.49%) |
May 5, 2026 24w ago | Press Release | $8.29 $6.88 | ▲ +17.01% | ▲ +19.79% | $6.26 (+24.49%) |
May 4, 2026 25w ago | 8-K | $8.90 $6.90 | ▼ −22.47% | ▼ −27.43% | $6.26 (−29.66%) |
May 4, 2026 25w ago | Press Release | $8.35 $7.19 | ▲ +13.89% | ▲ +19.54% | $6.26 (+25.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers